Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ulenistamab (Synonyms: PBP1510, PBP 1510)

Catalog No. T78306 Copy Product Info
Purity: 95%
🥰Excellent
Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody that specifically targets pancreatic adenocarcinoma upregulated factor (PAUF), Ulenistamab is extensively used in pancreatic cancer research to investigate PAUF-driven tumor progression, tumor microenvironment modulation, and antibody-based therapeutic strategies for pancreatic adenocarcinoma.

Ulenistamab

Copy Product Info
🥰Excellent
Catalog No. T78306
Synonyms PBP1510, PBP 1510

Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody that specifically targets pancreatic adenocarcinoma upregulated factor (PAUF), Ulenistamab is extensively used in pancreatic cancer research to investigate PAUF-driven tumor progression, tumor microenvironment modulation, and antibody-based therapeutic strategies for pancreatic adenocarcinoma.

Ulenistamab
Cas No. 2415259-90-2
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$289-In Stock
5 mg$753-In Stock
10 mg$1,180-In Stock
25 mg$1,770-In Stock
50 mg$2,380-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.4% (SDS-PAGE); 99.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody that specifically targets pancreatic adenocarcinoma upregulated factor (PAUF), Ulenistamab is extensively used in pancreatic cancer research to investigate PAUF-driven tumor progression, tumor microenvironment modulation, and antibody-based therapeutic strategies for pancreatic adenocarcinoma.
In vitro
In preclinical studies using human pancreatic cancer (PC) cell lines CFPAC-1 and BxPC-3, Ulenistamab treatment inhibited cell proliferation. The antibody reduced the metastatic potential of these cells by suppressing their migration and invasion capabilities [1].
In vivo
The pharmacokinetic (PK) profiles and immunogenicity of Ulenistamab (PBP1510) (up to 20 mg/kg) were examined in a single-dose study involving 6 monkeys. Systemic exposure in the monkey study was observed to increase in a dose-proportional manner at both low and high doses [1].
SynonymsPBP1510, PBP 1510
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetPAUF
Chemical Properties
Molecular Weight147.63 kDa
Cas No.2415259-90-2
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
StorageStore at low temperature | Store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Ulenistamab | purchase Ulenistamab | Ulenistamab cost | order Ulenistamab | Ulenistamab in vivo | Ulenistamab in vitro | Ulenistamab molecular weight